CARDIOTOXICITY OF INTERFERON - A REVIEW OF 44 CASES
CARDIOTOXICITY OF INTERFERON - A REVIEW OF 44 CASES
复制标题
DOI：
10.1378/chest.99.3.557
复制
发表时间：
1991-03-01
期刊：
影响因子：
9.6
通讯作者：
ROSIN, A
中科院分区：
文献类型：
--
作者：
SONNENBLICK, M;ROSIN, A
干扰素的临床试验中曾发生过心血管并发症。 我们在此回顾迄今为止所有类型的干扰素对癌症患者的心脏毒性的经验。 心脏毒性最常见的表现是心律失常、扩张型心肌病和缺血性心脏病的症状，包括心肌梗塞和猝死。 心脏效应与每日剂量、累积总剂量或治疗周期无关。 一些干扰素引起心血管后遗症的患者有冠心病病史或之前接受过已知具有心脏毒性的药物化疗。 在大多数患者中，停止药物治疗后心脏毒性是可逆的。
Cardiovascular complications have occurred in clinical trials of interferon. We review herein experience to date of cardiotoxicity with all types of interferons in cancer patients. The most common presentations of cardiotoxicity were cardiac arrhythmia, dilated cardiomyopathy, and symptoms of ischemic heart disease, including myocardial infarction and sudden death. The cardiac effects were not related to the daily dose, cumulative total dose, or period of therapy. Some of the patients in whom interferon has caused cardiovascular sequelae have had a history of coronary heart disease or have previously been given chemotherapy with drugs known to be cardiotoxic. In most of the patients, cardiac toxicity was reversible following the cessation of the drug therapy.